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ABSTRACT 
Objective: Resveratrol, a trihydroxystilbene, has been claimed to be a potent activator to SIRT-1 enzyme activity, which in turn could have a useful 
future application in the management of many chronic conditions such as metabolic syndrome and obesity. A group of novel tetrahydroxystilbene 
derivatives were isolated from Kangaroo Island propolis in Australia. Due to its structural similarities with resveratrol, the aim of this research was 
to explore the activity of Kangaroo Island prenylated stilbenes on SIRT-1 enzyme.  
Methods: In vitro fluorometry measurement of SIRT-1 enzyme activity using SIRT-1 assay kit (Cayman®).  
Results: None of the tested compounds had shown any activation to SIRT-1 enzyme, on contrary, they produced mild inhibition to the enzyme. 
Compound 3 (C20H22O4
Conclusion: Compound 3, in addition to compounds 2, 4, and 6 are candidate compounds for further investigation. A discussion of the results as 
well as the contradictory results in the literature has been presented in this article.  
, 3,5,4'-trihydroxy-3'-methoxy-2-prenyl-E-stilbene) was the most potent inhibitor.  
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INTRODUCTION 
Propolis is a sticky resinous material collected by honeybees from 
different plant origins, transported to the hive and mixed with bees 
wax. Propolis has an important role in maintaining a healthy hive for 
brood development. Also it can be used as an embalming substance 
to cover the body of dead insects which are too large to remove out 
of the hive. Propolis has shown to have strong biological activities 
including; antimicrobial, antioxidant, anti-inflammatory, hepato-
protective and anti-cancer activities [1, 2]. Propolis originated from 
Kangaroo Island, South Australia is a unique type of propolis which 
is rich in prenylated stilbenes (fig. 1). It is estimated that 75% of the 
ethyl acetate extract of Kangaroo Island propolis is stilbenes. Six of 
the prenylated stilbenes were novel compound in addition to a novel 
cinnamic acid derivative and chalcone [3]. SIRT1 is a member of Sir2 
family (class ΙΙΙ) which is a NAD-dependent histone deacetylase. 
Deacetylation by SIRT1 enzyme can target many substrates 
including histone, tumor suppressor p53, forkhead transcription 
factor (FOXO), peroxisome proliferator-activated receptor-γ 
(PPARγ) and co-activator-1α (PGC-1α) [4]. In humans, histone 
deacetylases are classified into four classes. Classes Ι, ΙΙ, ΙV are zinc 
ion-dependent for their activity, while class ΙΙΙ, which are also called 
“sirtuins”, is NAD+
SIRT1 has been shown to be involved in the regulation of many 
physiopathological processes like inflammation, cellular aging, 
apoptosis/proliferation, metabolism and cell cycle regulation [6]. 
Accordingly, SIRT1 activation could be a potential therapeutic target 
to control many diseases such as metabolic syndrome, obesity, 
neurodegenerative disorder, skeletal muscle dysfunction and aging-
related diseases [5]. On the other hand, many researcher observed 
an overexpression of SIRT1 enzyme in several cancers such as 
prostate cancer, colorectal cancer, hepatocellular carcinoma and 
leukemia [7]. Based on these observations, SIRT1 inhibition was 
proposed as a potential target for anticancer treatment [8]. The aim 
of this research was to investigate the in vitro effect of prenylated 
stilbenes (fig. 1) isolated from Kangaroo Island propolis on SIRT-1 
enzyme activity. 
-dependent for its catalytic activity. Seven 
homologs (SIRT1-SIRT7) have been identified from class ΙΙΙ. SIRT1 is 
the mammalian ortholog of Sir2p (silent information regulator 2 
protein) in the yeast Saccharomyces cervisiae [5].  
 
 
Fig. 1: Chemical structures of stilbenoids isolated from 
Kangaroo Island propolis 
 
MATERIALS AND METHODS 
Extraction and isolation 
The detailed procedures of extraction, isolation, elucidation of 
structures and identifying the botanical origin of Kangaroo Island 
propolis were mentioned in our previous works [3, 9]. In summary, 
propolis collected from Hog Bay Apiary (20 g) in Kangaroo Island 
was powdered and dissolved in 150 ml ethyl acetate (EtOAc). The 
mixture was stirred for 24 h in dark until a solution with suspended 
solid formed. The mixture was then filtrated twice to obtain ethyl 
acetate soluble fraction. The solvent evaporated and the residue 
then suspended in 150 ml dichloromethane (CH2Cl2) and loaded 
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into normal phase short-column vacuum chromatography (SCVC) to 
start the first SCVC. Elution was carried out with a step-wise 
gradient system of CH2Cl2
Fraction B was subjected to further normal-phase SCVC and afforded 
compound 1 (C
-EtOAc (1:0-3:1). As a result, 33 fractions 
were collected and grouped into four groups: A (f5-f8), B (f15-f20), C 
(f21-f29) and D (f30-f33). 
20H22O4, 5,4'-dihydroxy-3'-methoxy-3-prenyloxy-E-
stilbene), and compound 5 (C21H24O4, 5,4'-dihydroxy-3,3'-
dimethoxy-2-prenyl-E-stilbene). Fraction C was subjected to 
multistep fractionation and separation and resulted in the isolation 
of compound 7 (4',5'-dihydroxy-3,5-dimethoxy-E-stilbene), 
compound 8 (C19H20O2, Flavestin B), compound 9 (C19H20O4, 3',4',5-
trihydroxy-3-prenyloxy-E-stilbene), and compound 3 (C20H22O4




2Cl2-EtOAc followed by RP-HPLC using Econosil C18 
column and isocratic mobile phase of acetonitrile-H2O, which 
resulted in the isolation of compound 4 (C20H22O4, 5,3',4'-
trihydroxy-3-methoxy-2-prenyl-E-stilbene), compound 2 (C19H20O4, 
3,5,3',4'-tetrahydroxy-2-prenyl-E-stilbene) and compound 6 
(C14H12O4
SIRT1 direct fluorescent screening assay 
, piceatannol). 
The kit was purchased from Cayman chemical company, Michigan, 
USA. The procedure is based on two steps performed in the same 
microplate. In the first step, we incubate the substrate; which 
comprises the p53 sequence Arg-His-Lys-Lys(ε-acetyl)-AMC (7-
amino-methylcoumarin); along with its cosubstrate NAD+
To one of the thawed SIRT1 peptide vials add 240 µl of NAD
. 
Deacetylation sensitizes the substrate, such that treatment with the 
developer in the second step releases a fluorescent product which 
can be analysed using fluorimeter. 
+and 850 
µl of diluted assay buffer. The addition of 15 µl to the assay yields a 
final concentration of 125 µM peptide and 3 mM NAD+
% Inhibition/Activation = [(Initial activity–Sample)/Initial activity] x 100 
. For the 100% 
initial activity wells (3 wells), add 25 µl of assay buffer, 5 µl of 
diluted SIRT1, and 5 µl of solvent (DMSO). For background wells (3 
wells) add 30 µl of assay buffer and 5 µl of solvent. For 
Inhibitor/Activator wells (3 wells), add 25 µl of assay buffer, 5 µl 
diluted SIRT1, and 5 µl of inhibitor/activator. Initiate the reaction by 
adding 15 µl of substrate solution to all the wells being used. Cover 
the plate with the plate cover and incubate on a shaker for 45 min at 
room temperature. In order to prepare the stop/developing solution, 
weigh 30 mg of developer into a vial, then add 200 µl of 
nicotinamide and 4.8 ml of diluted assay buffer, vortex until the 
developer is into solution. Remove the plate cover and add 50 µl of 
stop/developing solution to each well. Cover the plate and incubate 
for 30 min at room temperature. Finally remove the plate cover and 
read the plate in a fluorimeter using an excitation wavelength of 
350-360 nm and an emission wavelength of 450-465 nm. Determine 
the average fluorescence of each sample and subtract the 
fluorescence of the background wells from the fluorescence of the 
100% initial activity and the inhibitor/activator wells. The 
experiment was carried out in two independent assays, each 
performed in triplicate. The results were calculated according to the 
following formula:  
RESULTS AND DISCUSSION 
The SIRT-1 assay kit utilises a substrate which comprises the p53 
sequence Arg-His-Lys-Lys (ε-acetyl)-AMC (7-amino-methyl-
coumarin) and a co-substrate (NAD+
 
). The fluorophore produced by 
the deacetylation reaction can be analysed using fluorometry. None 
of the compounds tested have shown any activation of the SIRT1 
enzyme. Actually all of the tested compounds showed mild inhibition 
(fig. 2). Resveratrol, which has been used as a positive control, 
showed a mild activation of almost two folds at a concentration of 
100 µM. The resveratrol metabolite with a hydroxyl group at 3’-
position, piceatannol (comp.6), completely reversed resveratrol 
activation of the SIRT-1 enzyme. Piceatannol (comp.6) produced 
mild inhibition to SIRT-1 enzyme. The replacement of the hydroxyl 
groups at position 3 and 6 by O-prenyl and methoxy groups 
respectively (comp.1) has resulted in a significant reduction of the 
inhibitory activity of piceatannol. The addition of a C-prenyl unit at 
position 4 (comp.2) slightly enhanced the inhibitory effect of 
piceatannol. Furthermore, when the hydroxyl groups at position 1 
and 3 were replaced by methoxy groups (comp.7), the inhibitory 
activity of piceatannol was significantly reduced. In relation to the 
effect of the methoxy group substitution on the C-prenylated 
tetrahydroxystilbene (comp.2), the substitution of methoxy group at 
position 6 (comp.3) has slightly increased the inhibitory activity on 
SIRT-1 enzyme; while the substitution of the same group at position 
3 (comp.4) did not produce any significant changes. Combining the 
two substitutions at positions 3 and 6 (comp.5) has significantly 
reduced the inhibitory activity on SIRT-1 enzyme. SIRT1 inhibition 
could be a potential target for the development of new anticancer 
treatment. In this experiment, comp.3 was the most potent inhibitor 
of SIRT-1 activity. 
 
Fig. 2: SIRT-1 activity for prenylated stilbenes from Kangaroo 
Island propolis at 3 concentrations (1, 10 and 100 µM). The 
results are expressed as % activity (mean±SEM) 
 
Kangaroo island propolis is a unique type of propolis which is rich in 
prenylated tetrahydroxystilbenes and prenylated cinnamic acid 
derivatives [3]. Stilbenes in general have been found to possess a 
wide range of pharmacological effects [10]. Resveratrol; a 
trihydroxystilbene; is the most studied stilbene and has shown to be 
a potent activator to SIRT-1 enzyme. This activation was claimed to 
increase the life span of yeast in experimental setting [11]. Many 
researchers have studied SIRT-1 activation and reported the 
therapeutic potential of such activation in many chronic conditions. 
On the other hand, some researchers hypothesized that activation of 
SIRT1 enzyme in healthy hepatic cells may work as a protective 
mechanism against cancer, but when cancer invades the liver, 
overexpression of SIRT1 enzyme will provide a survival mechanism 
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to cancer cells [12]. The over expression of SIRT-1 enzyme in some 
cancer cells highlighted the therapeutic potential of SIRT-1 
inhibitors as anticancer drugs [13]. 
The results of this research agree with some of the results in the 
literature and contradict others. In the first report published about 
resveratrol as an activator to SIRT1 enzyme, resveratrol doubled the 
rate of deacetylation at a concentration of 11 µM, and at 
concentration of 100 µM it increased the SIRT1 activity by almost 
13.5 fold. In the same research, piceatannol and quercetin (at conc. 
of 100 µM) increased SIRT1 activity by almost 8 and 5 fold 
respectively [11]; in this research piceatannol did not show any 
activation of the SIRT1 enzyme. In other research, the resveratrol 
concentration required to increase SIRT1 activity by 50% was found 
to be 46.2 µM, and they also found the maximum activation achieved 
was 2 fold at conc. of 100 µM [14]. Kahyo et al. examined the effect of 
a group of stilbenes on SIRT1 activity; (fig. 3); they identified 
piceatannol as the most potent activator, which increased the SIRT1 
activity by 3 fold. Resveratrol increased the activity by only 1.29 
fold, while quercetin showed very mild inhibition [4]. In general, all 
the stilbenes tested in that research showed mild inhibition to mild 
activation to SIRT1 enzyme (0.82–3.09 folds). 
 
 
Fig. 3: SIRT-1 activity of a group of stilbenes. The results are 
expressed as activity fold [4] 
 
On the other hand, Borra et al. found that resveratrol activated only 
human SIRT1, but not other sir2 homologs (yeast sir2 and human 
SIRT2), so linking the increase of yeast life span with resveratrol to 
the activation of sir2 enzyme is questionable. Although SIRT1 
activation by resveratrol was independent of peptide sequence, 
SIRT1 activation by resveratrol was dependent on the presence of 
fluorophore-containing substrate [15]. Similar results were obtained 
by another group of researchers and they found that the fluorophore 
decreases the binding activity of the peptide, and in the presence of 
resveratrol, the fluorophore-containing substrate bound more 
tightly to SIRT1 enzyme [16]. 
Another research claimed that activation of SIRT1 enzyme by 
resveratrol could be an experimental artefact, because in the 
absence of the fluorophore, the peptide itself is not a substrate for 
the enzyme. Furthermore, using either a p53-derived peptide 
substrate or acetylated PGC-1α isolated from cells (without 
fluorophore) did not activate SIRT1 in the presence of resveratrol 
[17]. When the assay was carried out using native substrates lacking 
fluorophore, such as p53-derived peptide or acetyl-CoA synthetase 
1, no apparent SIRT1 activation has been shown in the presence of 
resveratrol. Using NMR, surface Plasmon resonance and isothermal 
calorimetric techniques indicates that resveratrol directly interact 
with the fluorophore-containing peptide [18]. Recently, SIRT-1 
activation was found to be selective to the substrate sequences. By 
using peptide microarray assay, a 6802 physiologically occurring 
acetylation sites were tested in the presence and absence of 
resveratrol, SIRT-1 activation by resveratrol was strongly correlated 
with the presence of large hydrophobic residues at several positions 
C-terminal to acetyllysine in substrates. Interestingly, in some 
substrate sequences resveratrol was able to inhibit SIRT-1 activity 
[19]. Other researchers claimed that resveratrol indirectly activated 
SIRT-1 enzyme through the activation of AMP-activated protein 
kinase (AMPK). This effect was highly dose-dependent [20]. 
Recently, a group of researchers have added new insights into the 
interaction of resveratrol and SIRT-1 enzyme. They found that the 
presence of N-terminal domain in addition to catalytic domain of 
SIRT-1 was essential for the stimulatory effect of resveratrol. 3 
resveratrol molecules were found to mediate the interaction 
between SIRT-1 and p53-AMC peptide; two of these molecules are 
essential for the stimulatory effect and bind to the N-terminal 
domain of SIRT-1.  
By using isothermal titration calorimetry measurements, resveratrol 
was found to increase the binding between SIRT-1 and the fluorogenic 
peptide p53-AMC, when native peptides that lack the fluorophore such 
as PGC-1α and FOXO3a were used, no stimulation to SIRT-1 activity 
was found. The authors concluded that resveratrol works as an 
adaptor to strengthen the binding between the fluorogenic peptide 
and the N-terminal domain of SIRT-1 enzyme [21]. 
All previous contradictory evidence raises questions about the effect 
of resveratrol and probably other stilbenes on the activity of SIRT1 
enzyme. More investigation is required to clarify the situation. 
Limitations 
This is an in vitro preliminary investigation about the 
pharmacological effect of Kangaroo Island prenylated stilbenes on 
SIRT1 enzyme activity using Cayman SIRT1 assay kit. The results 
cannot be generalized to living tissues without a proper in vivo 
testing in living cells. Also, the commercial kit used a substrate that 
simulate a specific sequence of p53 protein, the effect of the tested 
compounds on other substrates such as histone, FOXO, p53, PPARγ 
and PGC-1α was not explored. Finally, the results of activation was 
measured only by increase fold of enzyme activity, but the effect on 
protein and mRNA levels was not investigated.  
CONCLUSION 
None of the tested stilbenes have shown any activation to SIRT-1 
enzyme. On the other hand compounds 2, 3, 4 and 6 have shown 
moderate inhibition to the enzyme activity. Further testing for these 
compounds is required to explore their potentials as anticancer 
candidates. 
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